Invivyd Q3 revenue rises on PEMGARDA demand, loss per share less than expected
IVVD•Invivyd's third-quarter revenue rose 18% year over year to $15.45 million, driven by PEMGARDA demand, while its $0.10 loss per share was below the $0.13 analyst estimate.
1. Quarterly results
Invivyd reported third-quarter revenue of $15.45 million, up 18% year over year, primarily driven by increased patient demand for PEMGARDA. The company posted a net loss of $33.47 million and a loss per share of $0.10, compared with analyst estimates of $39.51 million and $0.13, respectively.
2. Leadership and outlook
The company appointed Chairman Marc Elia as CEO. Invivyd expects interim Phase 3 data from its DECLARATION trial of VYD2311 imminently and said it is in dialogue with the FDA to refine and expand its accelerated regulatory approach. It is investing in commercial preparedness for VYD2311, with further updates expected in the first half of 2027.




